MaxCyte Q3 revenue down 25% to $8.0M, net loss widens; FY guidance reiterated

MAXCYTE, INC.

2023-Q3 EPS reported -$0.32 revenue$25,623,400

Total revenue $8.0M (-25% YoY); core business revenue $6.6M (-33%).
Net loss $11.3M vs $6.4M loss in Q3 2022; EBITDA loss $12.9M vs $7.1M.
Cell therapy revenue $4.7M (-40%); drug discovery $1.9M (-5%).
FY2023 guidance reaffirmed: total $34-36M, core $28-30M, SPL ~$6M.
Cash & investments $208.7M; expect ~$200M year-end.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

MAXCYTE, INC. reported the third quarter ended September 30, 2023 results: revenue Total revenue of $8.0 million in the third quarter of 2023, net income Third quarter 2023 net loss was $11.3 million. Guidance reaffirmed.

Period: the third quarter ended September 30, 2023
Revenue: Total revenue of $8.0 million in the third quarter of 2023
Net income: Third quarter 2023 net loss was $11.3 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative bioprocessing applications , today announced financial results for the third quarter ended September 30, 2023.

View on SEC.gov

21 earnings releases filed in the last 30 days. Browse all earnings releases →

MAXCYTE, INC. filing history →

Source: SEC EDGAR

accession 0001558370-23-018276

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.